A Lipid‐Sensitive Spider Peptide Toxin Exhibits Selective Anti‐Leukemia Efficacy through Multimodal Mechanisms

Bibliographic Details
Title: A Lipid‐Sensitive Spider Peptide Toxin Exhibits Selective Anti‐Leukemia Efficacy through Multimodal Mechanisms
Authors: Peng Zhang, Wu Luo, Zixin Zhang, Mingchong Lv, Longkang Sang, Yuhan Wen, Lingxiang Wang, Changhao Ding, Kun Wu, Fengjiao Li, Yueqi Nie, Jiaoyue Zhu, Xiaofeng Liu, Yan Yi, Xiaofeng Ding, Youlin Zeng, Zhonghua Liu
Source: Advanced Science, Vol 11, Iss 32, Pp n/a-n/a (2024)
Publisher Information: Wiley, 2024.
Publication Year: 2024
Collection: LCC:Science
Subject Terms: anticancer peptide, apoptosis, cell cycle arrest, ferroptosis, leukemia, PI3K‐AKT‐mTOR signaling pathway, Science
More Details: Abstract Anti‐cancer peptides (ACPs) represent a promising potential for cancer treatment, although their mechanisms need to be further elucidated to improve their application in cancer therapy. Lycosin‐I, a linear amphipathic peptide isolated from the venom of Lycosa singorensis, shows significant anticancer potential. Herein, it is found that Lycosin‐I, which can self‐assemble into a nanosphere structure, has a multimodal mechanism of action involving lipid binding for the selective and effective treatment of leukemia. Mechanistically, Lycosin‐I selectively binds to the K562 cell membrane, likely due to its preferential interaction with negatively charged phosphatidylserine, and rapidly triggers membrane lysis, particularly at high concentrations. In addition, Lycosin‐I induces apoptosis, cell cycle arrest in the G1 phase and ferroptosis in K562 cells by suppressing the PI3K‐AKT‐mTOR signaling pathway and activating cell autophagy at low concentrations. Furthermore, intraperitoneal injection of Lycosin‐I inhibits tumor growth of K562 cells in a nude mouse xenograft model without causing side effects. Collectively, the multimodal effect of Lycosin‐I can provide new insights into the mechanism of ACPs, and Lycosin‐I, which is characterized by high potency and specificity, can be a promising lead for the development of anti‐leukemia drugs.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2198-3844
Relation: https://doaj.org/toc/2198-3844
DOI: 10.1002/advs.202404937
Access URL: https://doaj.org/article/a7c1b7d685f2414688f35cf4e5c1c341
Accession Number: edsdoj.7c1b7d685f2414688f35cf4e5c1c341
Database: Directory of Open Access Journals
More Details
ISSN:21983844
DOI:10.1002/advs.202404937
Published in:Advanced Science
Language:English